Skip to content
Clinical Trials – home
RomaniaBack to Romania

Clinical trials in Resca – page 17

224 clinical trials in Resca, Romania. Every trial is listed in the EU Clinical Trials Register and updated daily.

RomaniaOur site in RomaniaStudii.Clinice.ro(opens in a new tab)
Resca at a glance
224
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

224 trials in Resca

Open in trial search

Hepatocellular carcinoma+14

Not recruiting

Study of INCB099280 for Patients with Advanced Solid Tumors Who Have Not Received Immunotherapy

InvestigationalNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:INCB099280
  • Sponsor:Incyte Corp.

Study of MK-7684A with Chemoradiotherapy Compared to Chemoradiotherapy with Durvalumab for Patients with Stage III Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Study Comparing Pembrolizumab Alone and with Sacituzumab Govitecan for Patients with Metastatic Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Study Comparing MK-7684A and Pembrolizumab for Patients with PD-L1 Positive Metastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Merck Sharp & Dohme LLC

Study of Belzutifan and Pembrolizumab for Patients with Renal Cell Carcinoma After Surgery

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

Study of Pembrolizumab and Olaparib with Chemoradiation for Patients with Stage III Non-Small Cell Lung Cancer

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Myelofibrosis

Not recruiting

Study on the Effectiveness and Safety of Selinexor and Ruxolitinib for Patients with Myelofibrosis Who Have Not Received Prior Treatment

Registered drug
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Aprepitant
  • Sponsor:Karyopharm Therapeutics Inc.

Study of Zipalertinib with Chemotherapy vs. Chemotherapy Alone for Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Taiho Oncology Inc.

Study of Adagrasib and Cetuximab for Patients with Advanced Colorectal Cancer with KRAS G12C Mutation After First-Line Therapy

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Mirati Therapeutics Inc.

Study of Adagrasib Dosing in Patients with Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation

InvestigationalNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Mirati Therapeutics Inc.

Study Comparing SGN-B6A and Docetaxel for Adults with Previously Treated Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Seagen Inc.

Study Comparing Repotrectinib and Crizotinib for Patients with Advanced or Metastatic ROS1-positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:RomaniaRomania
  • Participants:18–64 years · 65+ years
  • Substances:Crizotinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Other cities in Romania

The busiest research cities in the country

All 63 cities in Romania

Clinical research in Resca

What the registry says about research in the country

01 Infectious Disease Research

Ongoing clinical trials focusing on influenza prevention in elderly populations, evaluating advanced vaccine formulations with specialized adjuvants for enhanced immune response.

  • Vaccine Efficacy Studies
  • Immune Response Assessment
  • Prevention Strategies

Research aims to improve protection against influenza A and B strains through comparative analysis of adjuvanted and non-adjuvanted vaccine formulations in adults aged 65 and older.

02 Geriatric Medicine

Specialized vaccine research targeting the elderly population, with emphasis on developing more effective immunization strategies for vulnerable age groups.

  • Age-Specific Responses
  • Safety Monitoring
  • Immunogenicity Assessment

The research evaluates vaccine safety profiles and immune responses specifically tailored for older adults' unique health needs.

03 Vaccine Development

Advanced research into vaccine formulation technology, comparing different approaches to enhance protective immune responses against seasonal influenza.

  • Adjuvant Technology
  • Comparative Effectiveness
  • Clinical Protection

Studies focus on innovative vaccine technologies to improve prevention strategies against viral respiratory infections.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.